NOTICE OF 7-BUSINESS DAY PUBLIC COMMENT PERIOD
Rocket Pharmaceuticals Access and Affordability Plan for KRESLADI™
California Institute for Regenerative Medicine (CIRM)
Pursuant to CIRM’s Intellectual Property Regulations and Access and Affordability Plan requirements, the California Institute for Regenerative Medicine (“CIRM”) hereby provides notice of a 7-business-day public comment period regarding the proposed Access and Affordability Plan (“Access Plan”) submitted by Rocket Pharmaceuticals, Inc. (“Rocket”) for KRESLADI™ (marnetegragene autotemcel).
The public comment period will begin on Friday, August 28, 2026, and close on Tuesday, September 8, 2026.
The Access Plan describes Rocket’s proposed approach for providing access to eligible Californians who have “no other means” to obtain the Drug, as required by Proposition 14 and applicable CIRM regulations.
The non-confidential portions of the proposed Access Plan will be made available on CIRM’s website for public review and comment during the public comment period.
OPEN SESSION FOR PUBLIC COMMENT
Members of the public are invited to submit comments regarding the proposed Access Plan.
Written Comments
Written comments may be submitted during the public comment period by email to:
or by mail to:
California Institute for Regenerative Medicine
Attn: Legal Department
601 Gateway Blvd, #400
South San Francisco, CA 94080
Written comments must be received no later than 5:00 p.m. Tuesday, September 8, 2026.
Oral Comments
CIRM will provide an opportunity for oral public comment on the final day of the 7-business-day public comment period.
Date: Tuesday, September 8, 2026
Time: 9:00 a.m. – 9:30 a.m. Pacific Time
Location / Zoom Information:
- 601 Gateway Blvd, Suite 400
South San Francisco, CA 94080 - Dial in number: (669) 900-6833
Meeting ID: 816 1587 0728
Passcode: 260908
If the number of persons wishing to speak warrants, CIRM may limit the time allotted for each speaker in order to provide all interested persons an opportunity to be heard. Oral comments carry no greater weight than written comments.
Confidential Information
Certain portions of the Access Plan have been withheld from public disclosure because Rocket has identified those materials as containing confidential intellectual property, commercially sensitive information, and/or protected work product. CIRM has conducted a review of those confidentiality designations and finds them appropriate pursuant to applicable law, including Proposition 14 and the California Public Records Act.
CIRM Review Process
Following the close of the public comment period, CIRM will review all timely submitted comments prior to making a determination regarding approval of the Access Plan.
NOTICE
The California Institute for Regenerative Medicine complies with the Americans with Disabilities Act (“ADA”) by ensuring that meeting facilities are accessible to persons with disabilities and by providing this notice and related materials in appropriate alternative formats upon request.
If you require disability-related accommodations or modifications, please contact Claudette Mandac at 510-340-9101 #9193 or cmandac@cirm.ca.gov no later than the day prior to the meeting.
Questions or requests for additional information regarding this notice or the public comment process may be directed to legal@cirm.ca.gov.
This notice and related materials will also be available on CIRM’s official website.